||Relevant Treatment Approaches
BRAF V600E/K PTEN loss
Advanced Solid Tumor
predicted - sensitive
PX-866 + Vemurafenib
In a Phase I trial, the combination therapy of PX-866 and Zelboraf (vemurafenib) demonstrated safety and resulted in an objective response in 28% (5/18) of advanced solid tumor patients harboring BRAF V600E or K, and of those five patients, 80% (4/5) also demonstrated loss of PTEN (PMID: 29051322).